Publications l Reviews l Books

Publications related to hair follicle biology or clinical hair disorders:

• Andl T, Reddy ST, Gaddapara T, Millar SE. WNT signals are required for the initiation of hair follicle development. Developmental Cell 2(5):643-53, 2002.
  
  
• Bitoun E, Chavanas S, Irvine AD, Lonie L, Bodemer C, Paradisi M, Hamel-Teillac D, Ansai S, Mitsuhashi Y, Taieb A, de Post Y, Zambruno G, Harper JI, Hovnanian A. Netherton syndrome: disease expression and spectrum of SPINK5 mutations in 21 families. J Invest Dermatol 118(2):352-61, 2002.
  
  
• Cogen FC, Beezhold DH Hair glue anaphylaxis: a hidden latex allergy. Annals of Allergy, Asthma & Immunology 88(1):61-3, 2002.
  Hair bonding glue contains high concentrations of soluble latex antigen and can cause an IgE mediated reaction upon repeated exposure.
  
  
• Frisch M, Schwartz BS. The pitfalls of hair analysis for toxicants in clinical practice: three case reports. Environmental Health Perspectives 110(4):433-6, 2002.
  Hair analysis has been promoted by many non-physicians as a means of diagnosing a variety of diseases and conditions including metal toxicity. Many associated websites market products as therapy for "abnormalities" revealed by these hair analyses.
  
  In this article, the Division of Occupational and Environmental Health, Johns Hopkins Bloomberg School of Public Health, reviews the utility of hair analysis and reliability of hair analysis in clinical practice. Specifically, they review the appropriate means of screening for mercury toxicity (unstimulated urine and blood mercury) and lead burden (blood lead and chelatable lead, the latter by provocative challenge with either EDTA or DMSA), and the pitfalls of hair analysis to prove these (lack of validation of analytical techniques, presence of exogenous contaminants and variable analytic procedures, low interlaboratory reliability and poorly established reference values).
  
  
• Hutchinson PE. Hair density, hair diameter and the prevalence of female pattern hair loss. [letter; comment]. Br J Dermatol 146(5):922-3; discussion 923-4, 2002.
  
  
• Jamora C, DasGupta R, Kocieniewski P, Fuchs E Links between signal transduction, transcription and adhesion in epithelial bud development. Nature 2003 March 20;422(6929):317-22
  
  
• Kamimura A, Takahashi T. Procyanidin B-2, extracted from apples, promotes hair growth: a laboratory study. Br J Dermatol 146(1):41-51, 2002.
  
  
• Kljuic A, Bazzi H, Sundberg J, Martinwz-Mir A, O'Shaughnessy R, Mahoney M, Levy M, Montagutelli X, Ahmad W, Alta V, Gordon D, Uitto J, Whiting D, Ott J, Fischer S, Gilliam T, Jahoda C, Morris R et al. Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell 2003 April;113(2)249-60
  
  
• Lee HJ, Ha SJ, Lee JH, Kim JW, Kim HO, Whiting DA. Hair counts from scalp biopsy specimens in Asians. J Am Acad Dermatol 46(2):218-21, 2002.
  
  
• Li J, Tzu J, Chen Y, Zhang Y, Nguyen N, Gao j, Bradley M, Keene D, Oro A, Miner J, Marinkovich M Laminin-10 is crucial for hair morphogenesis Embo J. 2003, May 15;22(10):2400-10
  
  
• McElwee K, Kissling S, Wenzel E, Huth A, Hoffman R Cultured peribulbar dermal sheath cells can induce hair follicle development and contribute to the dermal sheath and dermal papilla. J Invest Dermatol. 2003 Dec;121(6):1267-75
  
  
• Muller FB, Hausser I, Berg D, Casper C, Maiwald R, Jung A, Jung H, Korge BP. Genetic analysis of a severe case of Netherton syndrome and application for prenatal testing. [Review] [15 refs]. Br J Dermatol 146(3):495-9, 2002.
  
  
• Murrin KL, Clarke DJ. Behavioral aspects of Pollitt syndrome: a 32-year follow-up of a case described by R.J. Pollitt and colleagues in 1968. J Intellectual Disability Res 46(Pt 3):273-8, 2002.
  
  
• Olsen E, Bergfeld W, Cotsarelis G et al Summary of North American Hair Research Society (NAHRS)Sponsored Workshop on Cicatricial Alopecia, Duke University Medical Centre, Feb 10 and 11. J. Am Acad Derm 48:103-110, 2003
  
  
• Ota Y, Saitoh Y, Suzuki S, Ozawa K, Kawano M, Imamura T. Fibroblast growth factor 5 inhibits hair growth by blocking dermal papilla cell activation. Biochemical and Biophysical Res Com. 290(1):169-76, 2002.
  
  
• Price VH, Menefee E, Sanchez M, Ruane P, Kaufman KD. Changes in hair weight and hair count in men with androgenetic alopecia after treatment with finasteride, 1 mg daily. J Am Acad Dermatol 46(4):517-23, 2002.
  Confirmatory study regarding finasteride effect on male pattern baldness. Sixty-six men with Hamilton II-IIIv who were randomized to receive placebo or finasteride 1 mg completed one year. Thirty-six continued for a 48 week-extension. Hair weights increased 20% for finasteride versus 5.2% for placebo at 48 weeks and increased 22% finasteride versus -2.4% for placebo at 96 weeks. Hair counts were 12.4% and 9.1% for finasteride and 3.2% and -6.3% for placebo at 48 and 96 weeks.
  
  
• Ruiz-Maldonado R. A previously unreported syndrome of multiple scalp whorls and associated anomalies. Clin & Exp Dermatol 27(1):21-3, 2002.
  
  
• Sakamoto F, Ito M, Saito R. Ultrastructural study of acquired pili torti-like hair defects accompanying pseudopelade. J Dermatol 29(4):197-301, 2002.
  
  
• Sharov AA, Li G, Palkina T, Sharova T, Gilchrest B, Botchkarev V Fas and c-kit are involved in the control of hair follicle melanocyte apoptosis and migration in chemotherapy induced hair loss. J Invest Dermatol. 2003 Jan:120(1)27-35
  
  
• Stough DA, Rao NA, Kaufman KD, Mitchell C. Finasteride improves male pattern hair loss in a randomized study in identical twins. Eur J Dermatol 12(1):32-7, 2002.
  
  
• The Finasteride Male Pattern Hair Loss Study Group. Long-term (5-year) multinational experience with finasteride 1 mg in the treatment of men with androgenetic alopecia. Eur J Dermatol 12(1):38-49, 2002.
  Five hundred and eighty-eight men aged 18-41 years old with Hamilton IIv - V male pattern baldness who participated in 2 years of placebo-controlled trial with finasteride 1 mg (Propecia) were followed for an additional 3 years. Efficacy was evaluated by hair counts, patient and investigator assessments and panel review of clinical photographs. Patients on placebo x 5 years lost a mean of -239 visible hairs/target area. Patients on finasteride x 4-5 years (variability dependent on whether on placebo in earlier part of study) had a mean increase of 38 visible hairs/target area. By global photograph assessment, approximately 50% finasteride treated patients had increased hair growth at month 60 versus 6% of placebo treated patients. 10% of those on finasteride versus 75% those on placebo demonstrated visible loss at 5 years. No new safety issues were raised.
  
  
• Wakelin SH. Contact anaphylaxis from natural rubber latex used as an adhesive for hair extensions. Br J Dermatol 146(2):340-1, 2002.
  
  
• Whittock NV, Wan H, Morley SM, Garzon MC, Kristal L, Hyde P, McLean WH, Pulkkinen L, Uitto J, Christiano AM, Eady RA, McGrath JA. Compound heterozygosity for non-sense and mis-sense mutations in desmoplakin underlies skin fragility/woolly hair syndrome. J Invest Dermatol 118(2):232-8, 2002.
  
  
• Zhang J, Tan X, Contag CH, Lu Y, Guo D, Harris SE, Feng JQ. Dissection of promoter control modules that direct Bmp4 expression in the epithelium-derived components of hair follicles. Biochemical & Biophysical Res Communications. 293(5):1412-9, 2002.
  
  

Reviewers for this segment:

• Elise Olsen, M.D. - Duke University Medical Center
• Kurt Stenn, M.D. - Bosley Medical

Books: